|Day Low/High||70.44 / 71.76|
|52 Wk Low/High||56.56 / 73.34|
These familiar names are displaying both technical and quantitative deterioration.
The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
The stock is trading above the 50-day and the 200-day moving averages.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
GE's problem can be summarized in one sentence: The company is burning cash.
I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
This contraction has been dramatic and unpredictable -- and best outcomes cannot be driven solely through economic creativity.
This is a lower probability trade, but with the coiled price action around BA, it wouldn't take much to spring this one to life.
* Mission accomplished? Sell in May and go away! * In scope and duration, stocks have rallied in a manner rarely seen in history * Month-to-date April has been the best month for equities since 1974 * The S&P Index has climbed by +31.4% since the M...
While the power of the Fed is unquestionable, there will be issues that liquidity simply can't fix.
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
Simple logic suggests that we won't be able to deny the significant economic damage that is being done forever.
There's now a much more reasonable chance the vast opening of American business won't lead to disaster.
The best play post-earnings over time on Tesla has been selling bullish put spreads that expire roughly two weeks into the close TOMORROW, the first day post-earnings.
We already know that the Fed is going to take all necessary measures to support the economy.
If you're looking for a longer-term market-related put play, here's something to consider.
I'm long GILD, but the fact is that the firm is not trying to make money off of Remdesivir at this point.
What's troubling many underinvested market participants is that there really has been no acknowledgment by the market of economic issues.
The S&P 500 and other U.S. equity futures have jumped after Gilead issued a statement saying it is aware of positive data emerging from a NIAID study of investigational antiviral remdesivir for the treatment of Covid-19. The NIAID is expected to pro...